Oppenheimer analyst Mohan Naidu reiterated a Buy rating on CVS Health (NYSE: CVS) on August 14 and set a price target of $85. The company’s shares closed yesterday at $73.20.
According to TipRanks.com, Naidu is a 5-star analyst with an average return of 15.5% and a 63.3% success rate. Naidu covers the Services sector, focusing on stocks such as Tivity Health Inc, Hms Holdings Corp, and Express Scripts.
Currently, the analyst consensus on CVS Health is a Strong Buy with an average price target of $82.71, which is a 13.0% upside from current levels. In a report issued on August 8, RBC Capital also reiterated a Buy rating on the stock with a $90 price target.
.
See today’s analyst top recommended stocks >>
CVS Health’s market cap is currently $74.44B and has a P/E ratio of 24.90. The company has a Price to Book ratio of 2.09.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CVS Health Corp. engages in the provision of health care services. It operates trough the following segments: Pharmacy Services, Retail or Long Term Care, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise.
